IGF1R and c-met as therapeutic targets for colorectal cancer

被引:34
|
作者
Shali, Hajar [1 ,2 ]
Ahmadi, Majid [3 ,4 ]
Kafil, Hossein Samadi [5 ]
Dorosti, Abbasali [6 ]
Yousefi, Mehdi [3 ,4 ]
机构
[1] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Students Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[4] Tabriz Univ Med Sci, Sch Med, Dept Immunol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Imam Reza Hosp, Sch Med, Dept Anesthesiol, Tabriz, Iran
关键词
Colorectal cancer; IGF1R; c-Met; Receptor tyrosine kinase; GROWTH-FACTOR-I; MONOCLONAL-ANTIBODY FIGITUMUMAB; FACTOR SIGNALING PATHWAY; FACTOR-BINDING-PROTEINS; INHIBITS TUMOR-GROWTH; FACTOR RECEPTOR; TYROSINE KINASE; COLON-CANCER; CARCINOMA CELLS; MEDIATED MIGRATION;
D O I
10.1016/j.biopha.2016.05.034
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The type 1 IGF receptor (IGF1R) and mesenchymal-epithelial transition (MET) are hetrodimeric and transmembrane receptor tyrosine kinases, which are frequently overexpressed by several tumor types, including colorectal cancer (CRC). These receptors bind to their specific ligands, insulin growth factors (IGFs) and hepatocyte growth factor (HGF), respectively, and promote signaling cascades which mediates many functions such as proliferation and protection against apoptosis, cell scattering, tumor cell motility, invasion and metastasis. In patients with metastatic colorectal cancer (mCRC), IGF1R and c-met expression confer resistance to cetuximab (monoclonal antibodies against EGFR). Therefore, the c-met and IGF1R are now an attractive novel target for anticancer therapy. In this review, we will describe correlation between two receptors and their activation effects in tumor cells, and finally introduce useful and available strategies for their targeting. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 50 条
  • [31] c-Met Signaling as a Therapeutic Target in Head and Neck Cancer
    Centuori, Sara M.
    Bauman, Julie E.
    CANCER JOURNAL, 2022, 28 (05): : 346 - 353
  • [32] Inhibition of c-Met as Therapeutic Strategy for Papillary Thyroid Cancer
    Bu, Rong
    Hussain, Azhar
    Ahmed, Saeeda
    Uddin, Shahab
    Al-Kuraya, Khawla
    CANCER RESEARCH, 2009, 69
  • [33] c-Met in pancreatic cancer stem cells: Therapeutic implications
    Marta Herreros-Villanueva
    Aizpea Zubia-Olascoaga
    Luis Bujanda
    World Journal of Gastroenterology, 2012, (38) : 5321 - 5323
  • [34] BIOLOGICAL AND THERAPEUTIC SIGNIFICANCE OF C-MET PATHWAY IN OVARIAN CANCER
    Wang, K. L.
    Wu, C. C.
    Hsu, Y. T.
    Chang, C. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 655 - 655
  • [35] Activated IGF1R in breast cancer with neoadjuvant chemotherapy
    Peiró, G
    Aranda, FI
    Adrover, E
    Alenda, C
    Peiró, FM
    Payá, A
    MODERN PATHOLOGY, 2006, 19 : 38A - 38A
  • [36] Activated IGF1R in breast cancer with neoadjuvant chemotherapy
    Peiró, G
    Aranda, FI
    Adrover, E
    Alenda, C
    Peiró, FM
    Payá, A
    LABORATORY INVESTIGATION, 2006, 86 : 38A - 38A
  • [37] Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
    Flanigan, Sara A.
    Pitts, Todd M.
    Newton, Timothy P.
    Kulikowski, Gillian N.
    Tan, Aik Choon
    McManus, Martine C.
    Spreafico, Anna
    Kachaeva, Maria I.
    Selby, Heather M.
    Tentler, John J.
    Eckhardt, S. Gail
    Leong, Stephen
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6219 - 6229
  • [38] Targeting IGF1R in osteosarcoma
    Vewinger, N.
    Beck, O.
    Wingerter, A.
    Russo, A.
    Seidmann, L.
    Backes, N.
    Roth, L.
    Paret, C.
    Faber, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1232 - S1232
  • [39] COMBINED IGF1R AND FAK INHIBITION AS A POTENTIAL THERAPEUTIC OPTION IN TRIPLE NEGATIVE BREAST CANCER
    MacMahon, D.
    Zhou, Z.
    Alcaide, T.
    Liu, T.
    McGlothen
    Taliaferro-Smith, L.
    O'Regan, R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S545 - +
  • [40] The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer
    Al-Saad, Samer
    Richardsen, Elin
    Kilvaer, Thomas K.
    Donnem, Tom
    Andersen, Sigve
    Khanehkenari, Mehrdad
    Bremnes, Roy M.
    Busund, Lill-Tove
    PLOS ONE, 2017, 12 (07):